Shares of Soligenix Inc. (SNGX) are soaring over 45% in pre-market today, after the company announced an agreement for the exclusive worldwide license of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp. (BSX), for the fields of SARS-CoV-2, the cause of COVID-19 and pandemic flu.
from RTT - Before the Bell https://ift.tt/2XGbiPB
via IFTTT
No comments:
Post a Comment